Sorrento Therapeutics, Inc. has announced positive results from a phase IIa study of Abivertinib for the treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) in China. Abivertinib is a novel Bruton's tyrosine kinase (BTK) inhibitor that targets BTK irreversibly. The study included 27 R/R MZL patients treated with Abivertinib, and the overall response rate (ORR) was 59.3%, with 3 patients achieving complete responses (CR). The disease control rate (DCR) was 92.6%. Progression-free survival (PFS) and duration of response (DOR) have not been reached yet. Sorrento plans to conduct a pivotal phase III registration study for R/R MZL in China.
 
Abivertinib is a pyrrolopyrimidine-based, mutant EGFR and BTK dual inhibitor that has potential across multiple indications. BTK inhibitors are widely used in cancer treatment and generated over $10.6 billion per year revenue in 2022